Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Impact of microarray data quality on genomic data submissions to the FDA

Nature Biotechnology volume 24, pages 1105–1107 (2006)Cite this article

How can microarray data best be exploited and integrated into the regulatory decision-making process?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Increase in formal requests (consults) for genomic data review (data submitted as part of regular INDs, NDAs or BLAs) to the Office of Clinical Pharmacology, and voluntary genomic data submissions (VGDS) to the FDA, since 2004.

References

  1. International Human Genome Sequencing Consortium. Nature 409, 860–921 (2001).

  2. Venter, J.C. et al. Science 291, 1304–1351 (2001).

    Article  CAS  Google Scholar 

  3. Lesko, L.J. & Woodcock, J. Pharmacogenomics J. 2, 20–24 (2002).

    Article  CAS  Google Scholar 

  4. http://www.fda.gov/cder/guidance/6400fnl.pdf

  5. http://www.cfsan.fda.gov/∼dms/opa-pt58.html

  6. Shi, L. et al. Expert Rev. Mol. Diagn. 4, 761–777 (2004).

    Article  Google Scholar 

  7. Shi, L. et al. BMC Bioinformatics 6 suppl. Suppl. 2, S12 (2005).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. US Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluationand Research, 10903 New Hampshire Avenue, Silver Spring, 20993, Maryland, USA

    Felix W Frueh

Authors
  1. Felix W Frueh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frueh, F. Impact of microarray data quality on genomic data submissions to the FDA. Nat Biotechnol 24, 1105–1107 (2006). https://doi.org/10.1038/nbt0906-1105

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0906-1105

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing